Application of galangin in prevention and treatment of osteoporosis by promoting osteogenic differentiation of bone marrow mesenchymal stem cells

A technology for bone marrow mesenchyme and osteoporosis, applied in the field of medicine, to achieve the effects of promoting osteogenic differentiation, promoting calcium salt nodule deposition, and increasing ALP activity

Inactive Publication Date: 2021-07-09
THE EIGHTH AFFILIATED HOSPITAL SUN YAT SEN UNIV
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] However, the use of galangin to induce osteogenic differentiation of bone marrow mesenchymal stem cells has not been reported

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of galangin in prevention and treatment of osteoporosis by promoting osteogenic differentiation of bone marrow mesenchymal stem cells
  • Application of galangin in prevention and treatment of osteoporosis by promoting osteogenic differentiation of bone marrow mesenchymal stem cells
  • Application of galangin in prevention and treatment of osteoporosis by promoting osteogenic differentiation of bone marrow mesenchymal stem cells

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1B

[0034] Determination of ALP activity in the process of embodiment 1BMSCs osteogenic differentiation

[0035] Alkaline phosphatase (ALP) is a marker for the maturation, differentiation and mineralization of early osteoblasts, and provides a material basis for the mineralization of bone cells to form bones. In this example, ALP activity was used as an index to evaluate the effect of galangin on the early osteogenic differentiation of BMSCs.

[0036] (1) Experimental grouping

[0037] This embodiment is divided into four groups altogether, i.e. control group (only use osteogenesis induction medium to carry out induction culture), drug low dosage group (use osteogenesis induction medium to dilute to the concentration of galangin liquid of 5 μ M), drug Middle dose group (galangin solution diluted to a concentration of 10 μM with an osteogenic induction medium), and high dose group (galangin solution diluted to a concentration of 20 μM with an osteogenic induction medium).

[0038] ...

Embodiment 2B

[0042] Alizarin red staining of embodiment 2 BMSCs osteogenic differentiation calcium salt nodules

[0043] Alizarin red staining is generally used to identify the mineralization of osteoblasts cultured in vitro. In this example, this staining method was used to evaluate the effect of galangin on the osteogenic differentiation of BMSCs.

[0044] (1) Measurement method

[0045] The resuscitated and digested bone marrow mesenchymal stem cells were administered according to the grouping and method in Example 3. After 14 days of osteogenic differentiation, the cells were observed under a microscope, and calcium salt nodules formed by osteogenic differentiation were deposited on the cell surface. After the cells were fixed, the cells were washed with PBS for 3 times, and then stained with Alizarin Red. After incubation at room temperature for 15 minutes, the cells were slowly washed with PBS for 3 times. The formation of calcium salt nodules was observed under a microscope, and the...

Embodiment 3

[0048] Example 3 Detection of Osteogenic Differentiation Levels by Western Blotting

[0049] (1) Determination method: The recovered and digested bone marrow mesenchymal stem cells were also administered according to the grouping and method in Example 3. After 14 days of osteogenic differentiation, cell samples were collected by adding cell lysate, and Western blotting was performed. The expression levels of the indicator proteins Runx2, OCN, and OPN proteins (with GAPDH as the internal reference) in the process of osteogenic differentiation were analyzed by using the method (references for specific operation methods: Tao K, Xiao D, Weng J, et al. Berberine promotes bonemarrow-derived mesenchymal stem cells osteogenic differentiation via canonical Wnt / β-catenin signaling pathway[J].Toxicology Letters,2016:68-80.).

[0050] (2) Measurement results: image 3 The assay results shown showed that the expression levels of Runx2, OCN, and OPN proteins in the cells were significantly...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the technical field of medicine, and particularly relates to application of galangin in prevention and treatment of osteoporosis by promoting osteogenic differentiation of bone marrow mesenchymal stem cells. The research finds that the galangin can improve ALP activity of the bone marrow mesenchymal stem cells cultured in vitro in the osteogenic differentiation process, promote deposition of calcium salt nodules, and up-regulate the expression level of the osteogenic differentiation related index protein so as to promote the osteogenic differentiation of the bone marrow mesenchymal stem cells, such that the osteoporosis relieving effect can be ultimately achieved, and the galangin can be used for preventing and treating osteoporosis, especially can be prepared into the drug for promoting the osteogenic differentiation of BMSCs or the drug for preventing and treating osteoporosis, and can be used for preventing and treating osteoporosis. The invention not only provides a new application direction of galangin, but also provides a new therapeutic drug and a new therapeutic approach for the treatment of osteoporosis.

Description

technical field [0001] The invention belongs to the technical field of medicine, and specifically relates to the use of galangin in preventing and treating osteoporosis by promoting osteogenic differentiation of bone marrow mesenchymal stem cells. Background technique [0002] Osteoporosis is a systemic and systemic metabolic disease characterized by low bone mass and microarchitectural destruction of bone tissue leading to increased fragility of the body. The disease is mainly caused by bone formation less than bone resorption in the body's bone metabolism. Osteoblasts and osteoclasts are the main cells that regulate the above process. Osteoclasts mainly mediate bone resorption to accelerate the occurrence of osteoporosis. Osteoblasts mainly secrete bone matrix and calcium salts during bone formation to Formation of new mature bone, thereby relieving osteoporosis. [0003] Bone marrow mesenchymal stem cells (BMSCs) are pluripotent stem cells derived from bone marrow, which...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/352A61K45/06A61P19/10A61P19/08
CPCA61K31/352A61K45/06A61P19/10A61P19/08
Inventor 沈慧勇吴燕峰曾琛莹旺姗王子明陈锋磊冯佩
Owner THE EIGHTH AFFILIATED HOSPITAL SUN YAT SEN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap